ABBV AbbVie Inc.
Company Analysis
Latest News
AbbVie Faces US National Security Probe Over China Clinical Trials
A bipartisan U.S. House committee has launched a national security investigation into AbbVie's clinical drug trials in China. The probe, led by the House...
AbbVie stock jumps 4.2% on positive EU regulatory opinions for RINVOQ
AbbVie received two positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for RINVOQ (upadacitinib). The...
AbbVie Hits Phase 3 Goal, Cutting Lymphoma Progression Risk by 60%
AbbVie announced positive topline results from its Phase 3 EPCORE DLBCL-4 trial for epcoritamab on June 29, 2026. The study evaluated epcoritamab in...
AbbVie shares jump 17%, driven by pediatric approvals and Apogee deal
AbbVie reported a 17% increase in its stock price during June 2026. The company secured expanded European Union approval for MAVIRET to treat acute and...
🟢 ABBV is trading 3.4% up today on $10.9 billion all-cash Apogee acquisition
ABBV is trading 3.4% higher at $251.38 following the announcement of a $10.9 billion all-cash acquisition of Apogee Therapeutics to expand its immunology...
🟢 ABBV is trading 3.1% up today following $10.9 billion acquisition of Apogee Therapeutics
• AbbVie announced the acquisition of Apogee Therapeutics for approximately $10.9 billion in an all-cash transaction. • The deal is expected to expand AbbVie's...
🟢 ABBV surges 6.1% in pre-market on continued momentum from $10.9 billion Apogee Therapeutics acquisition
ABBV is trading at $229.70, up 6.1% in pre-market, extending gains following its strategic acquisition of Apogee Therapeutics. • The pharmaceutical giant...
🟢 AbbVie Inc. extends move to 5.4% up
ABBV is trading at $228.10, up 5.4% versus the comparison close of $216.49 during regular trading. This is a price-movement alert; no separate company-specific...
AbbVie to acquire Apogee Therapeutics for $10.9B to expand immunology pipeline
AbbVie has entered into a definitive agreement to acquire Apogee Therapeutics, a clinical-stage biotechnology company, in an all-cash transaction valued at...
AbbVie Nears $10.9 Billion Apogee Deal, Strengthening Immunology Pipeline
AbbVie is nearing a $10.9 billion cash agreement to acquire Apogee Therapeutics. The proposed deal values the clinical-stage biotech at a 60% premium over its...
AbbVie Unveils Venclexta and Epcoritamab Data, Bolstering Oncology Market Position
AbbVie is presenting new blood cancer portfolio data at the European Hematology Association (EHA) 2026 Congress. Presentations include updates on approved and...
🟢 AbbVie Inc. shares rise 3.6% after its cancer drug Elahere wins NHS approval in England
AbbVie Inc. is trading at $225.00 (+3.6%) in pre-market after its ovarian cancer drug, Elahere, was approved for use by the NHS in England. • The approval...
🟢 AbbVie Inc. is trading 3% up today as shares extend a multi-day rebound amid a rotation into defensive healthcare
AbbVie Inc. is trading 3% up at $223.65, extending its recent multi-day rebound from last week’s pullback despite a lack of fresh company-specific...
AbbVie's Venclyxto Wins Expanded EU Approval for First-Line Leukemia Treatment
On May 29, 2026, AbbVie received European Commission authorization. This expands the label for its cancer drug, VENCLYXTO (venetoclax). The approval covers the...
AbbVie secures EU approval for Aquipta, offering dual-action migraine relief
AbbVie received European Commission approval for Aquipta (atogepant) on June 2, 2026. This authorization covers the acute treatment of migraine with or without...
AbbVie's first quarter 2026 revenue of $15.0B beat estimates, driven by strong Skyrizi and Rinvoq sales.
AbbVie reported first quarter 2026 revenue of $15.002 billion, a 12.4% year-over-year increase that surpassed analyst expectations of $14.78 billion. Adjusted...
AbbVie Inc Q1 2026 Earnings Preview: What Analysts Expect on April 29, 2026
AbbVie is expected to report Q1 2026 revenue of $14.78 billion and adjusted EPS of $2.69, with the stock currently trading at $198.71 against an average...
AbbVie and Regeneron Remain in Drug Pricing Talks as Johnson & Johnson Reaches Deal with U.S. Government
AbbVie Inc. remains in discussions with the White House over drug pricing, according to a Bloomberg report. The company is one of only two major pharmaceutical...
AbbVie Denies Revolution Medicines Acquisition Talks, Impacting Stock
AbbVie (ABBV) shares declined 3.98% after the company publicly denied being in advanced talks to acquire cancer-drug developer Revolution Medicines. The...
AbbVie Downgraded by Wolfe Research on Limited Upside Concerns
Wolfe Research downgraded AbbVie (ABBV) to 'Peer Perform.' The firm cited the company's strong performance over the last two years, arguing it leaves limited...